Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVEMIR vs LEVEMIR INNOLET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Insulin detemir is a long-acting basal insulin analogue. It binds to insulin receptors, activating downstream signaling pathways that promote glucose uptake in muscle and adipose tissue, inhibit hepatic gluconeogenesis, and suppress lipolysis and proteolysis. The myristic acid side chain enables reversible binding to albumin, resulting in slow and predictable absorption with a prolonged duration of action.
Insulin detemir is a long-acting recombinant human insulin analog. It binds to insulin receptors, activating tyrosine kinase signaling, which promotes cellular glucose uptake, inhibits hepatic gluconeogenesis, and suppresses lipolysis and proteolysis.
Improving glycemic control in adults and pediatric patients with diabetes mellitus (FDA-approved),Off-label: Use in gestational diabetes, hyperglycemia in hospitalized patients
FDA: Treatment of diabetes mellitus (type 1 and type 2) to improve glycemic control,Off-label: Gestational diabetes, hyperglycemia in hospitalized patients
Subcutaneous injection: 0.2 units/kg once daily or twice daily; usual total daily dose 0.5-1.0 units/kg. Adjust based on blood glucose levels.
0.2 units/kg subcutaneously once daily in the evening or twice daily (morning and evening) when used as basal insulin; titrate to target fasting glucose. For insulin-naive patients with type 2 diabetes, start at 10 units once daily in the evening. Dose adjustment of 1-4 units per day based on blood glucose monitoring.
Terminal elimination half-life: 13–18 hours (up to 24 hours with large doses); reflects prolonged absorption from subcutaneous depot due to dihexyl-deamination modification.
Terminal elimination half-life is 13–14 hours after subcutaneous administration, providing a flat, protracted pharmacokinetic profile suitable for once-daily dosing.
Insulin detemir is extensively bound to albumin (98-99%). Hepatic metabolism is not significant; it is degraded by proteolytic enzymes into inactive metabolites.
Insulin detemir is metabolized via non-CYP450 pathways, primarily proteolytic degradation. The main metabolite is inactive.
Renal: minimal, as insulin is extensively reabsorbed and degraded in the proximal tubule; hepatic metabolism: via receptor-mediated endocytosis and degradation by insulin-degrading enzyme; biliary/fecal: negligible.
Hepatic metabolism (deamidation at B30 and deacetylation at B29) and subsequent renal excretion; ~30% of dose excreted unchanged in urine.
Bound to albumin (>98%); also binds to insulin receptors.
>98% bound to albumin; binding is reversible and saturated at therapeutic concentrations.
0.26–0.57 L/kg; reflects distribution primarily into extracellular fluid and tissues with high insulin receptor density.
Volume of distribution is approximately 0.26–0.38 L/kg, reflecting distribution primarily into interstitial fluid.
Subcutaneous: approximately 85–90%.
Subcutaneous: approximately 60–80% absolute bioavailability; not administered by other routes.
No specific dose adjustment recommended based on GFR; monitor glucose closely in renal impairment due to increased risk of hypoglycemia.
For GFR <30 m L/min: consider dose reduction and more frequent monitoring due to decreased insulin clearance; start with lower doses and titrate cautiously. No specific dose adjustment guidelines for GFR 30-89 m L/min, but monitor closely.
No specific Child-Pugh based dose adjustments; monitor glucose closely in hepatic impairment due to altered glucose metabolism.
Child-Pugh Class A (mild): no dose adjustment required. Child-Pugh Class B (moderate): start with lower doses and titrate slowly due to impaired gluconeogenesis and reduced insulin clearance. Child-Pugh Class C (severe): use with caution; consider starting at 50% of standard dose and titrate based on response.
Children ≥2 years: 0.2-0.5 units/kg subcutaneously once daily or twice daily; titrate based on glucose monitoring.
For children aged 2 years and older with type 1 diabetes: start at 0.2-0.5 units/kg subcutaneously once daily in the evening. For type 2 diabetes: limited data; based on adult dosing. Adjust dose based on blood glucose targets. Do not mix with other insulins.
Initiate at lower doses (e.g., 0.1-0.2 units/kg once daily) to minimize hypoglycemia risk; titrate cautiously.
In elderly patients (age ≥65 years), start at lower doses (e.g., 0.1 units/kg subcutaneously once daily) due to increased risk of hypoglycemia. Titrate slowly and monitor renal function. Avoid aggressive dose escalation.
Never share a Levemir Flex Pen, Pen Fill cartridge, or vial between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
None
Monitor for hypoglycemia, which may be severe and life-threatening,Accidental mix-ups between insulin products can occur; verify label before administration,Changes in insulin regimen should be made cautiously and under medical supervision,Patients with renal or hepatic impairment may be at higher risk for hypoglycemia,May cause fluid retention and worsening of heart failure when used with thiazolidinediones,Hypersensitivity reactions including anaphylaxis, rash, and urticaria may occur,Hypoglycemia and hypokalemia are potential adverse effects
Hypoglycemia: May be life-threatening; dose adjustment needed with renal/hepatic impairment,Medication errors: Do not confuse with other insulins; not for IV or IM use,Hypokalemia: Can cause low potassium, leading to cardiac arrhythmias,Fluid retention and heart failure: When used with thiazolidinediones (TZDs)
Hypoglycemia (during episodes),Hypersensitivity to insulin detemir or any of its excipients
Hypoglycemia episodes,Hypersensitivity to insulin detemir or excipients,Not recommended for diabetic ketoacidosis (use short-acting insulin)
No specific food interactions, but timing of meals should be consistent to align with insulin action. Avoid large fluctuations in carbohydrate intake without dose adjustment. Alcohol may increase risk of hypoglycemia.
No specific food interactions. Advise consistent carbohydrate intake to match insulin dose. Alcohol may increase hypoglycemia risk; avoid or limit alcohol consumption.
Insulin detemir (LEVEMIR) does not cross the placenta in significant amounts; no teratogenic effects in animal studies. In humans, poor glycemic control is associated with fetal risks, but insulin detemir itself is not considered teratogenic. Risk of maternal hypoglycemia and fetal harm if dosing is poorly managed.
Insulin detemir does not cross the placenta in significant amounts. Animal studies show no evidence of teratogenicity. In humans, no increased risk of major malformations in first trimester; risks in second and third trimesters relate to maternal hyperglycemia, not drug. Poor glycemic control increases risk of fetal anomalies, macrosomia, neonatal hypoglycemia.
Insulin detemir is a large protein molecule and is not expected to transfer into breast milk in significant amounts. No specific M/P ratio available. It is considered compatible with breastfeeding; monitor infant for signs of hypoglycemia.
Insulin detemir is excreted in human milk in low amounts, unlikely to affect the infant. M/P ratio not reported. It is a peptide that is degraded in infant GI tract. Use during breastfeeding is considered compatible with caution to monitor infant blood glucose if maternal dose is high.
Insulin requirements typically increase during pregnancy, especially in the second and third trimesters. Dose adjustments may be needed; start with frequent glucose monitoring and titrate doses accordingly. Postpartum, reduce dose to prepregnancy levels.
Pregnancy increases insulin requirements, especially in second and third trimesters. Dose adjustments typical: first trimester may require 0-20% reduction due to increased hypoglycemia risk; second trimester increase by 50-70%; third trimester increase by 100-150% above pre-pregnancy doses. Frequent monitoring and titration are essential.
Levemir (insulin detemir) is a long-acting basal insulin analogue with a flat action profile lasting up to 24 hours. It has a lower risk of hypoglycemia compared to NPH insulin. Dose adjustments are needed in renal or hepatic impairment. Do not mix with other insulins in the same syringe. Onset is slower than glargine; administer once or twice daily at the same time each day.
Levemir (insulin detemir) is a long-acting basal insulin analog with a duration of action up to 24 hours. It has a lower risk of hypoglycemia compared to NPH insulin due to its flat pharmacokinetic profile. Administer once or twice daily at the same time(s) each day. Do not mix with other insulins in the same syringe. Store unopened vials/penfills in refrigerator; opened pens can be kept at room temperature (<30°C) for up to 42 days. Monitor renal and hepatic function as dose adjustments may be needed.
Inject subcutaneously into abdomen, thigh, or upper arm; rotate sites within the same region.,Never mix Levemir with other insulins in the same syringe.,Do not use if solution appears cloudy or thickened; it should be clear and colorless.,Store unused vials/penfills in refrigerator (2-8°C); in-use pens can be kept at room temperature below 30°C for up to 42 days.,Monitor blood glucose regularly and watch for signs of hypo- or hyperglycemia.,Do not change insulin type or dose without consulting your healthcare provider.,Discard needles after each use; never share pens or needles.
Inject subcutaneously into abdomen, thigh, or upper arm; rotate injection sites to avoid lipodystrophy.,Do not mix with other insulins; use a separate injection site if combining therapies.,Check blood glucose regularly and record results; know symptoms of hypoglycemia and hyperglycemia.,Do not use if solution appears cloudy or has particles; it should be clear and colorless.,Store unopened pens in refrigerator; opened pens can be kept at room temperature for up to 42 days away from heat or light.,Missed dose: take as soon as remembered unless next dose is due within 6 hours; never double dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVEMIR vs LEVEMIR INNOLET, answered by our medical review team.
LEVEMIR is a Antidiabetic (Long-Acting Insulin) that works by Insulin detemir is a long-acting basal insulin analogue. It binds to insulin receptors, activating downstream signaling pathways that promote glucose uptake in muscle and adipose tissue, inhibit hepatic gluconeogenesis, and suppress lipolysis and proteolysis. The myristic acid side chain enables reversible binding to albumin, resulting in slow and predictable absorption with a prolonged duration of action.. LEVEMIR INNOLET is a Antidiabetic (Long-Acting Insulin) that works by Insulin detemir is a long-acting recombinant human insulin analog. It binds to insulin receptors, activating tyrosine kinase signaling, which promotes cellular glucose uptake, inhibits hepatic gluconeogenesis, and suppresses lipolysis and proteolysis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVEMIR and LEVEMIR INNOLET depend on the specific clinical indication. These are both Antidiabetic (Long-Acting Insulin) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVEMIR is: Subcutaneous injection: 0.2 units/kg once daily or twice daily; usual total daily dose 0.5-1.0 units/kg. Adjust based on blood glucose levels.. The standard adult dose of LEVEMIR INNOLET is: 0.2 units/kg subcutaneously once daily in the evening or twice daily (morning and evening) when used as basal insulin; titrate to target fasting glucose. For insulin-naive patients with type 2 diabetes, start at 10 units once daily in the evening. Dose adjustment of 1-4 units per day based on blood glucose monitoring.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVEMIR and LEVEMIR INNOLET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVEMIR is classified as Category C. Insulin detemir (LEVEMIR) does not cross the placenta in significant amounts; no teratogenic effects in animal studies. In humans, poor glycemic control is associated with fetal ri. LEVEMIR INNOLET is classified as Category C. Insulin detemir does not cross the placenta in significant amounts. Animal studies show no evidence of teratogenicity. In humans, no increased risk of major malformations in first . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.